Identification of Novel Imidazo[1,2- b ]pyridazine Derivatives as Selective ROCK2 Inhibitors for the Treatment of Pulmonary Fibrosis
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c02233 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Zhi Cao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China. Hauptthemen laut MEDLINE: rho-Associated Kinases, Pyridazines, Pulmonary Fibrosis, Protein Kinase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Liaoning Revitalization Talents Program, China Postdoctoral Science Foundation, Development Project of Ministry of Education Innovation Team.
Abstract (Originalsprache)
Rho-associated coiled-coil containing protein kinase 2 (ROCK2) has been identified as a promising target for the treatment of pulmonary fibrosis (PF). In this study, a series of novel imidazo[1,2-b]pyridazine derivatives were designed as selective ROCK2 inhibitors. Through comprehensive investigation of SARs, compounds A25 and A26 exhibited superior ROCK2 inhibitory potency (IC50 = 7.0 and 8.7 nM, respectively) and excellent isoform selectivity (SI = 200/138). In bleomycin-induced PF mice models, administration of A25 and A26 resulted in a pronounced reduction of collagen deposition and a significant reversal of fibrotic progression. Mechanism study confirmed that A25 exerted antifibrotic effects via the TGF-β/Smad and ROCK2/STAT3 signaling pathways. Furthermore, A25 exhibited a favorable safety profile, showing low hERG channel inhibition and almost no pathological alterations in major organs. Overall, A25 was identified as a promising lead compound for the development of selective ROCK2 inhibitors for PF therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
ORCID-Profile: Xin Zhai
Förderung
- Liaoning Revitalization Talents Program
- China Postdoctoral Science Foundation
- Development Project of Ministry of Education Innovation Team
Zitieren
APA
Cao, Z., Wang, S., Ma, J., Du, J., Wei, X., Yue, L., Zhang, J., Tan, Z., & Zhai, X. (2025). Identification of Novel Imidazo[1,2- b ]pyridazine Derivatives as Selective ROCK2 Inhibitors for the Treatment of Pulmonary Fibrosis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02233
Vancouver
Cao Z, Wang S, Ma J, Du J, Wei X, Yue L, et al. Identification of Novel Imidazo[1,2- b ]pyridazine Derivatives as Selective ROCK2 Inhibitors for the Treatment of Pulmonary Fibrosis. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02233
BibTeX
@article{Cao2025,
author = {Cao, Zhi and Wang, Shuqi and Ma, Jiajun and Du, Jiyu and Wei, Xiujian and Yue, Lingfeng and Zhang, Jiahao and Tan, Zehui and Zhai, Xin},
title = {Identification of Novel Imidazo[1,2- b ]pyridazine Derivatives as Selective ROCK2 Inhibitors for the Treatment of Pulmonary Fibrosis},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c02233}
}
EUVIMED